Walleye Capital
CTNM

Walleye Capital’s Contineum Therapeutics CTNM Stock Holding History

Walleye Capital’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-44,185
Closed -$778K – 5965
2024
Q2 		$778K Buy
+44,185
New +$712K ﹤0.01% 3089

Other funds holding CTNM

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Walleye Capital's CTNM Position: Q3 2024 in Review

Walleye Capital sold out of Contineum Therapeutics (CTNM) in Q3 2024, closing a stake of 44,185 shares — an estimated $778K sold.

Walleye Capital first reported a position in CTNM in Q2 2024 and held it in 1 quarter. The position peaked at $778K in Q2 2024. 52 funds tracked by Wall St. Rank hold CTNM as of Q3 2024.

  • Walleye Capital reported no remaining Contineum Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 44,185 Contineum Therapeutics shares in Q3 2024, an estimated $778K.
  • Walleye Capital first reported a position in Contineum Therapeutics in Q2 2024 and held it in 1 quarter.
  • Walleye Capital's Contineum Therapeutics position peaked at $778K in Q2 2024.
  • 52 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.